Methods for predicting a patient's response to egfr inhibitors

C - Chemistry – Metallurgy – 12 – Q

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12Q 1/02 (2006.01) G01N 33/48 (2006.01)

Patent

CA 2721687

The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an EGFR inhibitor, such as an EGFR tyrosine kinase inhibitor or a molecule targeting the extracellular domain of EGFR.

La présente invention concerne des méthodes permettant d'individualiser la chimiothérapie pour le traitement du cancer, plus particulièrement, permettant d'évaluer la sensibilité d'un patient à un ou plusieurs inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) avant un traitement au moyen de tels agents. En particulier, cette invention concerne un dosage biologique permettant des chimioréponses in vitro pour prédire une réponse d'un patient à un inhibiteur EGFR, tels qu'un inhibiteur tyrosine kinase EGFR ou une molécule ciblant le domaine extracellulaire de EGFR.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods for predicting a patient's response to egfr inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for predicting a patient's response to egfr inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for predicting a patient's response to egfr inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1775340

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.